Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
复制标题
DOI：
10.1097/01243894-200606000-00011
复制
发表时间：
2006-06-01
影响因子：
20.4
通讯作者：
Johnson, David H.
中科院分区：
文献类型：
--
作者：
Wakelee, Heather A.;Wang, Wei;Johnson, David H.
前言：以前的数据表明，女性晚期非小细胞肺癌（NSCLC）患者的寿命可能比男性更长。我们在东部肿瘤协作组（ECOG）E1594试验中评估了性别是否影响生存率。E1594随机晚期非小细胞肺癌患者的四个铂doublets之一，发现所有四个方案具有可比的efficacy.Patients和方法：患者在E1594数据库中被分为男性和女性队列，反应和生存分别为每个队列计算。已知的预后因素和毒性特征的差异进行了比较两个cohols.Results：所有1157名符合条件的患者（431名女性，726名男性）从E1594被列入本分析。女性和男性之间在体能状态、体重减轻> 10%、分期或脑转移发生率方面没有统计学显著差异。应答率相似（两者均为19%; P = 0.15）。然而，女性的中位生存时间显著延长，为9.2个月（95% CI，8.1-10.4个月），而男性仅为7.3个月（95% CI，6.8-8.0个月）（P = 0.004对数秩检验）。毒性一般是更大的妇女比在mense.Conclusions：妇女在ECOG 1594有1.9个月的统计学显着改善中位生存期与男性相比，尽管类似的反应率和更大的毒性，并没有其他已知的预后因素的差异。这些数据强烈支持性别作为晚期NSCLC的独立预后因素的重要性，并强调性别作为未来III期NSCLC试验分层因素的重要性。
Introduction: Previous data suggest that women may live longer with advanced non-small cell lung cancer (NSCLC) than men. We evaluated whether sex affected survival in the Eastern Cooperative Oncology Group (ECOG) E1594 trial. E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy.Patients and Methods: Patients in the E 1594 database were divided into male and female cohorts; response and survival were calculated separately for each cohort. Known prognostic factors and differences in toxicity profiles were compared between the two cohorts.Results: All 1157 eligible patients (431 women, 726 men) from E1594 were included in this analysis. There was no statistically significant difference in performance status, weight loss of >10%, stage, or incidence of brain metastases between women and men. Response rates were similar (19% for both; P = 0.15). The median survival time for women, however, was significantly longer at 9.2 months (95% CI, 8.1-10.4 months) versus only 7.3 months for men (95% CI, 6.8-8.0 months) (P = 0.004 log-rank test). Toxicity was generally greater in women than in men.Conclusions: Women in ECOG 1594 had a 1.9-month statistically significant improvement in median survival compared with men, despite similar response rates and greater toxicity and no difference in other known prognostic factors. These data strongly support the significance of sex as a separate prognostic factor in advanced NSCLC and emphasize the importance of sex as a stratification factor in future phase III NSCLC trials.